Gene Therapy: The Basics. Mark A. Kay MD PhD Dennis Farrey Family Professor Stanford University

Similar documents
This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform

Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy

Genetics and Genomics in Medicine Chapter 9 Questions

Regulatory Perspectives on Gene Therapies for Rare Diseases Rare Diseases Forum Washington, D.C. October 17, 2018

Genetic Engineering in Agriculture

Discovery of drugs and drug resistance. Model organisms. Plants and livestock. Cell-based disease modelling. Therapeutics

Sangamo BioSciences Reports Third Quarter 2013 Financial Results

Welcome to the Webinar! Human Genome Editing: Latest Developments and Advancements

New Plant Breeding Technologies

Immuno-Oncology Program

ALLERGAN ENTERS STRATEGIC R&D ALLIANCE WITH EDITAS MEDICINE TO DISCOVER AND DEVELOP CRISPR GENE EDITING PROGRAMS FOR OCULAR DISEASES

THE CRISPR-CAS9 DISPUTE

CRISPR/Cas9 From Yoghurt to Designer Babies. Source: nextbigfuture.com

Image adapted from: National Human Genome Research Institute

HUMAN GENOME EDITING FAQs

Bart Williams, PhD Van Andel Research Center

Genome editing. Knock-ins

Issues in production of viral gene transfer vectors. Stefan Kochanek Department of Gene Therapy Ulm University

Corporate Presentation. March 2018

Hemophilia and Gene Therapy

GENE TECHNOLOGY LEGISLATION

Biosafety Committees and Biological Materials Oversight: Past, Present and Future for Clinical Research

Basic Concepts and History of Genetic Engineering. Mitesh Shrestha

Thoughts on Gene Editing Francis Collins, M.D. U.S. National Academies Human Gene Editing Committee July 12, 2016

Chapter 9. Biotechnology and DNA Technology

Q4 and Full Year 2017 Conference Call. February 22, 2018

CNS Gene Regulation Platform

SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

Gene Therapy Clinical Pipeline

10/07/2018. Liver directed gene therapy. - An overview. DNA/RNA therapies for Wilson s disease. The liver, organ of choice. Highly vascularised

Updates to the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines)

17.5 Eukaryotic Transcription Initiation Is Regulated by Transcription Factors That Bind to Cis-Acting Sites

Biological Research Registration Form

JUST THE FACTS 1. Nearly 300 Cell and Gene Therapies in Development for A Broad Range of Diseases

Sangamo BioSciences Reports First Quarter 2014 Financial Results

Gene therapies for SMA and DMD

Genetics Faculty of Agriculture and Veterinary Medicine. Instructor: Dr. Jihad Abdallah Topic 16: Biotechnology

Course Agenda. Day One

Presidential Commission for the Study of Bioethical Issues 2 nd meeting September

Achievement Level Descriptors for Medical Interventions

Genome editing: Principles, Current and Future Uses

Voyager Therapeutics - A Spinout from UMass Gene Therapy and RNAi Technologies

Regulatory Pathways for Rare Diseases

Regulation of metabolic pathways

Comparability Is Not a Nightmare, Just Think Ahead!

Goal 3. Friday, May 10, 13

Gene Therapy for Fanconi Anaemia Hope or hype? Dr Phil Ancliff Great Ormond Street Hospital / UCL Institute of Child Health Twycross Zoo October 2017

Gene therapy. Findings by Alert

BIOTECHNOLOGY. Understanding the Application

Chapter 10 Genetic Engineering: A Revolution in Molecular Biology

sirna Overview and Technical Tips

What goes into my Biological Inventory?

Development Stage of Therapeutic Vaccines: The Regulator s View

Molecular Analysis of Genes and Gene Products. BIT 220 Chapter 22

BIOTECHNOLOGY. Understanding the Application

Principles and perspectives of gene therapy

GREAT STRIDES IN SCIENCE WHAT ABOUT ACCESS? Marlene E. Haffner, MD, MPH 2nd IRDiRC Conference Shenzhen, China November 8, 2014

Germline Gene Therapy

Adoptive cellular therapies are based on the administration of live cells into a patient in order for them to serve a therapeutic purpose.

Q Earnings and Corporate Developments. October 31, 2018

Genomics and Biotechnology

Genome Engineering. Brian Petuch

Genetics and Biotechnology Chapter 13

Application of RNA Interference to Anti-Doping. Matthew Fedoruk, Ph.D. Gene & Cell Doping Symposium 2013, Beijing, China

VECTOR SAFETY INFORMATION. AAV Vectors: Material Information

Chapter 8: DNA and RNA

Update from the Center for Biologics Evaluation and Research (CBER) Peter Marks, M.D., Ph.D. GMP By The Sea 2017

Target Selection in the area of Gene Therapy Harald Petry, PhD

SANGAMO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

CRISPR cas : Presented By: Pooya Rashvand Advised By: Dr. M.Aslanimehr

Sangamo BioSciences Reports Third Quarter 2014 Financial Results

ARTICLE DISCUSSION: MARCH 2018 IRB MEMBER TRAINING

Regulatory Requirements for CRISPR Therapeutics. Bill Lundberg, MD February 2017

Basics of recombinant DNA medical biotechnology. Lecture VI

Sumiti Jain. [Poster #2003, Tuesday February 13 th ] February 12 th, 2018

Yale University Biological Safety Committee

Advancing Manufacturing for Advanced Therapies

Groups of new plant breeding techniques

Cell and Gene Therapy Catapult clinical trials database

Chapter 9 Genetic Engineering

Return to Web Version

Mutagenesis and Expression of Mammalian Clotting Factor IX. Mark McCleland The Children s Hospital of Philadelphia and Lycoming College

Medical Topics: Gene Therapy. E. Anne Jackson, FSA MAAA July 30, 2018

Biotechnology and DNA Technology

Introduction to CRISPR/Cas9 Background DNA Cleavage and Repair (NHEJ and HDR) Alternative Cas9 Variants Delivery of Cas9 and sgrna Library Products

Pre-existing anti-viral vector antibodies in gene therapy

Could benefit organic: High use in Hawaii has lowered virus levels to allow organic production. Herd immunity

Genetic tests are available for hundreds of disorders. DNA testing can pinpoint the exact genetic basis of a disorder.

2054, Chap. 14, page 1

Advances in Crop BiotechnologyCisgenics and Genome Editing

Principles and perspectives of gene therapy

Therapeutic & Prevention Application of Nucleic Acids

Molecular Biology (2)

Understanding Gene Therapy. April 26, 2016

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform

Gene Therapy for MYO7A USH1B. Shannon Boye, Ph.D. Assistant Professor Department of Ophthalmology University of Florida

Dr. Gary Mumaugh. DNA Technology

Chapter 8 Healthcare Biotechnology

Gene Therapy and Emerging Molecular Therapies

AdenoVerse Platform for Translational Development of Innovative Gene and Cell Therapies Cell & Gene Therapy World January 18, 2017

Transcription:

Gene Therapy: The Basics Mark A. Kay MD PhD Dennis Farrey Family Professor Stanford University

Definition of gene therapy Gene therapy is the introduction of nucleic acids (e.g. DNA/genes) into somatic cells of the body to correct or prevent a pathological process Think of DNA as a class of pharmaceuticals

What do we want to accomplish? Add a gene (gene addition) to: supply functionally deficient protein or provide a protein with therapeutic effects (most current clinical trials) Fix a mutation in the gene Knockdown or knock out a gene: gain-of-function or viral infection

Vectors Types of vectors used to incorporate exogenous DNA into a cell Friedman, Scientific American 1997

Vectors used for gene expression strategies must contain a few essential components promoter coding sequence poly-a site Or non coding DNA 5 3 Other sequences can be included--- Examples: Enhancers Introns Regulatory sequences (to enhance expression or restrict expression to a specific cell type)

Potential factors limiting vector efficacy

AAV Vectors AAV ITR Rep Cap ITR DNA AAV Vectors ITR Control element Gene Cassette Therapeutic DNA ITR DNA

Pseudotyping Recombinant Vector Genomes AAV2 AAV1 AAV3 AAV4 AAV5 AAV6 Small number of amino acid changes can have profound effects on the transduction parameters (immunity, efficiency, cell type)

A Problem Animal Models Do Not Necessarily Predict Human Outcome

Recent Successes A form of retinal eye blindness Car-T for certain blood cancers Immunodeficiency (e.g. Bubble Boy Disease) Hemophilias A and B Parkinson Disease

Why was hemophilia an early targeted gene therapy Small and large animal models that recapitulate the disease Well known correlation between level of factor and severity of disease As little as a 1 to 2 percent is therapeutic No need to have strict gene regulation

Hemophilia B Gene Therapy Trial

What are the challenges? How to include patients with pre-existing immunity to the vector CTL response and possible insertional mutagenesis Getting the dosing right How long will it last? Re-administration? Manufacturing

What do we want to accomplish?-2 Silencing a Gene Silence a gene from a pathogen, gain-of-function mutation CCR5 Sensitive to HIV CCR5-Δ32 Resistant to HIV

Silencing a Gene by Gene Therapy and RNAi

Genome Editing to Silence a Gene or manipulate specific region of genome Different nucleases-enzymes that exist in nature that cleave specific DNA sequences. (e.g. CCR5) These can be modified to recognize a sequence of interest. Examples-homing endonucleases, Zn-finger nucleases, Talens, CRISPR-Cas9 Non-enzyme mediated gene recombination Sickle Cell Anemia vs Beta- thalassemia

Mysterious RNAs and Gene Therapy Non- protein coding RNAs are the dark matter of the cell Over 95% of DNA genome is made into RNA but only a few percent make proteins What do these RNAs do and how can we manipulate them to treat disease?

The <$1000 Genome In the not too near future everyone will be offered genome sequencing Neonatal blood spots replaced Predisposition loci identified Health choices and gene therapy prevention (just like a vaccine!!!)

Acceptable Therapy? Horrific Diseases to Traits Examples: Neuro psychiatric diseases: bipolar, schizophrenia, addiction (OCD), drug reactions, antisocial behavior, intelligence, athletic coordination, sexual preferences etc etc.